|1.||Boroojerdi, Babak: 20 articles (01/2015 - 05/2005)|
|2.||Schollmayer, Erwin: 14 articles (01/2016 - 12/2004)|
|3.||Trenkwalder, Claudia: 12 articles (01/2014 - 03/2008)|
|4.||Surmann, Erwin: 10 articles (12/2014 - 01/2011)|
|5.||Kohnen, Ralf: 9 articles (12/2013 - 12/2004)|
|6.||Braun, Marina: 8 articles (04/2015 - 02/2009)|
|7.||Cawello, Willi: 8 articles (04/2015 - 02/2009)|
|8.||Poewe, Werner: 8 articles (07/2013 - 07/2008)|
|9.||Stiasny-Kolster, Karin: 8 articles (06/2013 - 12/2004)|
|10.||Högl, Birgit: 8 articles (01/2013 - 03/2008)|
|1.||Parkinson Disease (Parkinson's Disease)
03/01/2007 - "Clinical trials demonstrate the efficacy of rotigotine in early and advanced Parkinson's disease, with important implications for treatment of non-motor symptoms of Parkinson's disease."
01/01/2005 - "Patients with early Parkinson's disease receiving rotigotine monotherapy experienced significantly greater improvements in parkinsonian symptoms (as measured by Unified Parkinson's Disease Rating Scale scores) compared to placebo in two large, well designed clinical trials. "
01/01/2008 - "Rotigotine improved HR-QOL in both early Parkinson's disease (one study) and more advanced disease with motor fluctuations (one study). "
01/23/2007 - "Transdermal rotigotine, when titrated to a dosage of 6 mg/24 h, was effective for the treatment of early-stage Parkinson disease in this trial. "
09/01/2006 - "Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. "
|2.||Restless Legs Syndrome (Restless Legs)
07/01/2008 - "Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial."
03/01/2008 - "Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe."
07/01/2008 - "Our aim was to investigate the efficacy of transdermal rotigotine in the treatment of idiopathic restless legs syndrome. "
01/01/2016 - "Effects of rotigotine on daytime symptoms in patients with primary restless legs syndrome: a randomized, placebo-controlled study."
04/01/2015 - "The aim of this study was to summarize the efficacy and tolerability of rotigotine in the treatment of primary restless legs syndrome (RLS). "
12/01/2011 - "In patients with inadequate early morning motor control despite antiparkinsonian treatment, rotigotine improved morning motor functioning and reduced sleep disturbances, night-time motor symptoms, depressive symptoms, pain and functioning, and quality of life to a significantly greater extent than placebo. "
08/01/2011 - "Rotigotine improved morning motor functioning and reduced sleep disturbances, night-time motor symptoms, depressive symptoms, pain and functioning, and quality of life to a significantly greater extent than placebo. "
01/01/2014 - "The results from this post hoc analysis of the RECOVER study suggest that pain was improved in patients with PD treated with rotigotine; this may be partly attributable to benefits in motor function and sleep disturbances. "
09/01/2011 - "Though this trial was not powered for statistical subgroup analysis, these post hoc results indicate that treatment with rotigotine may benefit patients with sleep, pain, mood and quality-of-life issues."
01/01/2014 - "Change from baseline pain scores decreased with rotigotine compared with placebo in patients with 'any' pain (-0.88 [95% CI: -1.56, -0.19], p = 0.013), and in the subgroup with 'moderate-to-severe' pain (-1.38 [-2.44, -0.31], p = 0.012). "
01/01/2010 - "These data suggest that dyskinesia induced by pulsatile drug treatment may be improved by switching to continuous rotigotine delivery. "
12/01/2014 - "Of 596 participants who received open-label rotigotine, 299 (50%) remained at trial closure; no patient discontinued due to dyskinesia. "
12/01/2014 - "During treatment with rotigotine in patients with PD for up to 6 years the incidence of dyskinesia was low, and the dyskinesia was generally 'not disabling' or 'mildly disabling'."
01/01/2010 - "In addition, while continuous delivery of rotigotine may prime for dyskinesia, it does not lead to its expression."
01/01/2010 - "Initial treatment with a continuous infusion of rotigotine for 28 days reversed motor disability and resulted in a low incidence of dyskinesia. "
|5.||Parkinsonian Disorders (Parkinsonism)
01/01/2014 - "Behavioral and neurophysiological effects of transdermal rotigotine in atypical parkinsonism."
09/01/2013 - "Low doses of rotigotine in patients with antipsychotic-induced parkinsonism."
01/01/2015 - "Recently, the transdermal rotigotine has been proposed for the treatment of atypical parkinsonism, as well as deep brain stimulation (DBS) of the peduncolopontine nucleus alone or combined with globus pallidus internus stimulation. "
01/01/2014 - "Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy."
10/01/2014 - "Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study."
|1.||Levodopa (L Dopa)
|2.||Dopamine Agonists (Dopamine Agonist)
|5.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|7.||Dopamine Receptors (Dopamine Receptor)
|9.||amsonic acid (DAS)
|2.||Activities of Daily Living (ADL)
|3.||Electric Stimulation Therapy (Electrotherapy)